Abstract
Globally, cardiovascular disease (CVD) remains the leading cause of mortality and morbidity, accounting for some 18 million deaths worldwide in 2015, and this is expected to grow to >23.6 million by 2030. The biggest cause of cardiovascular death is ischemic heart disease (IHD), for both men and women. Global CVD rates rose by 12.5% between 2005 and 2015, with deaths attributable to IHD increasing by 16.6% to 8.9 million deaths, whilst age-standardised mortality rates fell by 12.8%, reflecting improved survival. IHD is largely attributable to atherosclerosis, a complex, chronic inflammatory process, determined by both genetic and environmental factors. Advances in the understanding of atherosclerotic plaque morphology, acute alterations in plaque morphology associated with acute coronary thrombotic events, and the complex interplay with a prothrombotic milieu and inflammation, have led to the concept of a “vulnerable patient”, rather than just a vulnerable plaque. There remains an important, ongoing need to further reduce mortality and morbidity from IHD, and an appreciation of the pathophysiology of IHD is essential to enable this.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Epidemiology
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.
Atherosclerosis
Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.
Arbab-Zadeh A, Fuster V. The myth of “the vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol. 2015;65(8):846–55.
Boudoulas KD, Triposciadis F, Geleris P, Boudoulas H. Coronary atherosclerosis: pathophysiologic basis for diagnosis and management. Prog Cardiovasc Dis. 2016;58(6):676–92.
GW Stone for PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
Michel J-B, Martin-Ventura JL, et al. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis. 2014;234:311e319.
Nikpay M, et al. A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–30.
Yahagi K, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13:79–98.
Ischemia Reperfusion, Preconditioning, Postconditioning
Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000;190(3):255–66.
Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317.
Vinten-Johansen J, Shi W. Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. J Cardiovasc Pharmacol Ther. 2011;16(3-4):260–6.
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–35.
Stunning, Hibernation
Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999;79:609–34.
Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103–14.
Depre C, Vatner SF. Cardioprotection in stunned and hibernating myocardium. Heart Fail Rev. 2007;12(3–4):307–17.
Slezak J, Tribulova N, Okruhlicova L, Dhingra R, Bajaj A, Freed D, Singal P. Hibernating myocardium: pathophysiology, diagnosis, and treatment. Can J Physiol Pharmacol. 2009;87(4):252–65.
SVG Disease
Yahagi K, Kolodgi FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13(2):79–98.
ISR
Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659–73.
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897–907.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Gorog, D. (2018). Coronary Heart Disease. In: Myat, A., Clarke, S., Curzen, N., Windecker, S., Gurbel, P.A. (eds) The Interventional Cardiology Training Manual. Springer, Cham. https://doi.org/10.1007/978-3-319-71635-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-71635-0_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-71633-6
Online ISBN: 978-3-319-71635-0
eBook Packages: MedicineMedicine (R0)